Eisai reports positive new Fycompa trial data

Eisai has presented new clinical data supporting the safety and efficacy of Fycompa at the International Epilepsy Congress in Istanbul.

The perampanel-based treatment was shown to significantly reduce seizure frequency, both in patients with primary generalised tonic-clonic (PGTC) seizures and partial epilepsy in new phase III clinical trials.

A subset analysis of the recently published Study 332 showed seizure frequency was reduced by 62.3 percent – versus 31.7 percent for placebo – in patients having PGTC seizures with idiopathic generalised epilepsy.

Meanwhile, it was also revealed that 8.6 percent of patients were seizure-free at six months in a retrospective analysis of Spanish data from 315 patients with partial-onset seizures.

Eugen Trinka, chair of the department of neurology at the Christian Doppler Klinik at Paracelsus Medical University, said: "These results illustrate that perampanel's novel mechanism of action yields an excellent response in terms of seizure frequency, when used adjunctively with existing anti-seizure therapies, across the most common seizure types."

The drug was launched in the UK as a treatment for PGTC seizures in adults and adolescents with idiopathic generalised epilepsy earlier this year.